Pancreatic Cancer Action Network

Pancreatic cancer remains one of the deadliest cancers because it is often detected at an advanced stage when treatment options are limited.

Pancreatic cancer is one of the most challenging cancers to treat.

This month’s Research Spotlight highlights significant advancements in pancreatic cancer research and patient support.

The recent American Cancer Society’s Cancer Statistics, 2025 report was released revealing a sobering trend for pancreatic cancer.

From Patrick Swayze’s widow recalling his pancreatic cancer diagnosis to Demi Moore speaking about her aunt’s courage during cancer, here’s what’s going on in the oncology space this week.

With Leadership from Pancreatic Cancer Action Network (PanCAN) Champions in Congress, House Defense Appropriations Bill Passes with Increase to Pancreatic Cancer Research Program at Department of Defense.

Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies.

Researchers found that patients with pancreatic cancer receiving chemotherapy saw worse survival outcomes when taking Ativan, commonly prescribed to treat anxiety. What other mental health options are available?

PanCAN Has Invested More Than $208 Million Over 20 Years Aimed at Building the Field of Pancreatic Cancer Researchers and Finding More Breakthroughs for Patients.

Patients with pancreatic cancer are treated with chemotherapy and surgery, depending on the stage, but more options are needed to treat a disease does not often respond to treatment.

One expert discussed the importance of understanding the different stages of pancreatic cancer and why the disease may be often diagnosed in later stages.

Addition marks first experimental therapy offered as either first- or second-line option for pancreatic cancer patients enrolled in novel trial platform.

The other half of the Siegfried and Roy duo famous for their Vegas act died on Thursday from terminal pancreatic cancer.

The research process for pancreatic cancer is long and difficult, but a new method of clinical trials is looking to adapt to a growing field and find ways to speed up research without losing efficiency.

Adaptive Clinical Trial Design Is More Cost Effective, Patient-Centric and Allows for Faster Learning Than Standard Trials

Adaptive clinical trials are poised to deliver hope to patients with pancreatic cancer.

“Sometimes ‘a new normal’ seems to have a bad connotation,” said Nicole Lise Feingold, director of Patient Services at the Pancreatic Cancer Action Network (PanCAN).